119866 Direct

This is the Investigational New Drug (IND) number for , an interleukin-13 receptor antagonist developed by Dermira Inc. (and later Eli Lilly) for treating moderate-to-severe atopic dermatitis.

This refers to the published by the United Nations High Commissioner for Refugees (UNHCR) in October 2025. 119866

Progressed through clinical trials, eventually leading to the FDA-approved product Ebglyss . This is the Investigational New Drug (IND) number